Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipratropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 6/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.98 |
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | BLM | P54132 | 4/20 | 0.77 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipratropium SCHEMBL22077027 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL22077028 | 0.99 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL1476940 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL820105 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL1476937 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL65495 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL19665229 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL12210779 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL15502093 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL19665230 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860580-A2 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | Kindeva Drug Delivery L.P. (US) | 2021-08-11 | — | — | EP | claimed |
| WO-2020070620-A2 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-04-09 | — | — | WO | claimed |
| US-20100137357-A1 | COMPOSITIONS AND METHODS FOR HYPERHIDROSIS | KOLENG JOHN J | 2010-06-03 | — | — | US | claimed |
| WO-2010062930-A1 | COMPOSITIONS AND METHODS FOR HYPERHIDROSIS | DRY PHARMA, LLC (US) | 2010-06-03 | — | — | WO | claimed |
| US-20240226004-A1 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | JPMORGAN CHASE BANK, N.A. | 2024-07-11 | — | — | US | disclosed |
| EP-3860580-A2 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | Kindeva Drug Delivery L.P. (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020070620-A2 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-2007349-B1 | AEROSOL SUSPENSION FORMULATIONS COMPRISING TG 227 EA OR TG 134 A AS PROPELLANTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2017-08-02 | — | — | EP | disclosed |
| US-8518377-B2 | Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant | BOEHRINGER INGELHEIM PHARMA GBMH CO. KG (DE) | 2013-08-27 | — | — | US | disclosed |
| US-8357352-B2 | Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| EP-1809243-B1 | AEROSOL SUSPENSION FORMULATIONS CONTAINING TG 227 EA AS A PROPELLANT | BOEHRINGER INGELHEIM INT (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20100137357-A1 | COMPOSITIONS AND METHODS FOR HYPERHIDROSIS | KOLENG JOHN J | 2010-06-03 | — | — | US | disclosed |
| WO-2010062930-A1 | COMPOSITIONS AND METHODS FOR HYPERHIDROSIS | DRY PHARMA, LLC (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20090092559-A1 | Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant | BOEHRINGER INGELHEIM PHARMA GBMH CO. KG (DE) | 2009-04-09 | — | — | US | disclosed |
| EP-2007349-A1 | AEROSOL SUSPENSION FORMULATIONS COMPRISING TG 227 EA OR TG 134 A AS PROPELLANTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007118802-A1 | AEROSOL SUSPENSION FORMULATIONS COMPRISING TG 227 EA OR TG 134 A AS PROPELLANTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1809243-A2 | AEROSOL SUSPENSION FORMULATIONS CONTAINING TG 227 EA OR TG 134 A AS A PROPELLANT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-25 | — | — | EP | disclosed |
| CN-1984642-A | Aerosol suspension formulations containing TG 227 ea or TG 134 a as a propellant | BOEHRINGER INGELHEIM INT (DE) | 2007-06-20 | — | — | CN | disclosed |
| WO-2006002840-A2 | AEROSOL SUSPENSION FORMULATIONS CONTAINING TG 227 EA OR TG 134 A AS A PROPELLANT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-12 | — | — | WO | disclosed |
| US-20060002863-A1 | Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090092559-A1 | Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant | TCOF1, TCERG1, PTGER1 | CHRM3 1067/4885CHRM2 1533/4885CHRM5 1629/4885 |
| US-20100137357-A1 | COMPOSITIONS AND METHODS FOR HYPERHIDROSIS | CHRM3, ACHE, CHRM5 | CHRM3 1/4885CHRM2 5/4885CHRM5 3/4885 |
| US-20240226004-A1 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | MCOLN3, SYMPK, ADRB2 | CHRM3 20/4885CHRM2 47/4885CHRM5 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.